Hematologic Oncology | Specialty

Clinical Trials in AML: Frontline Use of FLT3 Inhibitors

September 20th 2018

Implications of the RATIFY Trial in Acute Myeloid Leukemia

September 20th 2018

AML: An Overview of Available FTL3 Inhibitors

September 20th 2018

FLT3 Mutations' Impact on Prognosis and Treatment in AML

September 20th 2018

Establishing the Role of FLT3 Mutations in AML

September 20th 2018

Breaking Down the Epidemiology of AML

September 20th 2018

Dr. Shah on Treatment of Patients with p53-Mutated MCL

September 20th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Dr. Tasian on Challenges in Treating Pediatric Patients With Ph-Like ALL

September 19th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the challenges in treating pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).

Dr. Rule on the Role of BTK Inhibitors in MCL

September 18th 2018

Simon Rule, MD, PhD, professor of Hematology at Plymouth University Medical School, United Kingdom, discusses the role of BTK inhibitors in the treatment of patients with mantle cell lymphoma.

Dr. Kin on Triplet Regimens for Relapsed Multiple Myeloma

September 18th 2018

Andrew Kin, MD, assistant professor, Karmanos Cancer Institute, discusses triplet regimens for the treatment of patients with relapsed multiple myeloma.

Dr. Scherber on the Treatment of Myelofibrosis

September 18th 2018

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the treatment of patients with myelofibrosis.

Novel Ruxolitinib Approaches Explored in Myelofibrosis

September 17th 2018

Researchers are exploring combination approaches with ruxolitinib (Jakafi) in myelofibrosis as a potential strategy for reinvigorating the drug’s effect in patients who progress, relapse, or become intolerant on single-agent treatment with the JAK inhibitor.

Carfilzomib Combos Deemed Safe in Multiple Myeloma

September 15th 2018

Updated safety data of the ASPIRE and ENDEAVOR trials showed that carfilzomib-based (Kyprolis) regimens demonstrate benefit across patient populations of multiple myeloma.

Dr. Lesokhin on the Current Treatment Landscape of Myeloma

September 14th 2018

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape for patients with multiple myeloma.

Venetoclax/Navitoclax Regimen Is Effective, Safe in Lymphoblastic Lymphoma and ALL

September 14th 2018

Phase I data showed that combining venetoclax and navitoclax plus chemotherapy demonstrated encouraging responses and tolerability in patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma.

Dr. Pinilla-Ibarz on the FDA Approval of Moxetumomab Pasudotox in Hairy Cell Leukemia

September 13th 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the FDA approval of moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

FDA Approves Moxetumomab Pasudotox for Hairy Cell Leukemia

September 13th 2018

The FDA has approved moxetumomab pasudotox for the treatment of adult patients with relapsed or refractory hairy cell leukemia following at least 2 prior lines of therapy.

Novel Agents Lead Charge Against Adult ALL

September 13th 2018

Julio C. Chavez, MD, discusses prognostic indicators and systemic treatment updates for patients with acute lymphoblastic leukemia.

Dr. Shain Discusses the Role of Stem Cell Transplant in Myeloma

September 12th 2018

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses the evolving role of stem cell transplant in the treatment of patients with multiple myeloma.

Dr. Raje Discusses the Impact of bb2121in Myeloma

September 12th 2018

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the impact of bb2121 in myeloma.